[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100434198":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":32,"studyPopulation":32,"armGroups":42,"interventions":54,"overallOfficials":60,"centralContacts":64,"locations":73,"responsibleParty":101,"collaborators":32,"id":103,"slug":32,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":104,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":32,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":76,"whyStopped":32,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Centre Hospitalier Henri Laborit","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Yale Brown Obsessive Compulsive Scale score","Significant clinical change (≥ 25%) from baseline to two weeks after the treatment sequence, assessed by a significant reduction in YBOCS scores at day 25","baseline and 25 days",[14,18,21,23,26,28],{"measure":15,"description":16,"timeFrame":17},"Yale Brown Obsessive Compulsive Scale","Significant clinical change of the YBOCS score (≥25% decrease), from baseline to day 70","baseline and 70 days",{"measure":19,"description":20,"timeFrame":12},"general assessement functioning (GAF)","Change of the general assessement functioning (GAF) at day 25",{"measure":19,"description":22,"timeFrame":17},"Change of the general assessement functioning (GAF) at day 70",{"measure":24,"description":25,"timeFrame":12},"Clinical Global Impression (CGI)","Clinical Global Impressions (CGI) change at day 25",{"measure":24,"description":27,"timeFrame":17},"Clinical Global Impressions (CGI) change at day 70",{"measure":29,"description":30,"timeFrame":31},"Adverse events linked to the rTMS treatment","Number and types of adverse events linked to the rTMS treatment","70 days",null,{"allocation":34,"interventionModel":35,"interventionModelDescription":32,"primaryPurpose":36,"observationalModel":32,"timePerspective":32,"maskingInfo":37},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":38,"maskingDescription":32,"whoMasked":39},"DOUBLE",[40,41],"PARTICIPANT","INVESTIGATOR",[43,49],{"label":44,"type":45,"description":46,"interventionNames":47},"Active stimulation","EXPERIMENTAL","Active rTMS stimulation , 2 session per day during 10 days.",[48],"Device: rTMS Treatment",{"label":50,"type":51,"description":52,"interventionNames":53},"Sham Stimulation","SHAM_COMPARATOR","Sham rTMS stimulation , 2 session per day during 10 days.",[48],[55],{"type":56,"name":57,"description":58,"armGroupLabels":59,"otherNames":32},"DEVICE","rTMS Treatment","1 Hz rTMS",[44,50],[61],{"name":62,"affiliation":5,"role":63},"Ghina Harika-Germaneau","STUDY_DIRECTOR",[65,70],{"name":66,"role":67,"phone":68,"phoneExt":32,"email":69},"Ghina Harika-Germaneau, MD, PhD","CONTACT","+33 5 16 52 61 18","ghina.harika.germaneau@ch-poitiers.fr",{"name":71,"role":67,"phone":68,"phoneExt":32,"email":72},"Nematollah Jaafari, PR","nemat.jaafari@ch-poitiers.fr",[74,90],{"facility":75,"status":76,"city":77,"state":32,"zip":32,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":86},"Sorbonne University, Pitié-Salpêtrière Hospital","RECRUITING","Paris","France","FR",{"type":81,"coordinates":82},"Point",[83,84],2.3488,48.85341,{"lat":84,"lon":83},[87],{"name":88,"role":67,"phone":32,"phoneExt":32,"email":89},"Bruno Millet, PR","b.millet@aphp.fr",{"facility":5,"status":76,"city":91,"state":32,"zip":92,"country":78,"countryCode":79,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Poitiers","86021",{"type":81,"coordinates":94},[95,96],0.34348,46.58261,{"lat":96,"lon":95},[99],{"name":66,"role":67,"phone":68,"phoneExt":32,"email":100},"ghina.harika-germaneau@ch-poitiers.fr",{"type":102,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100434198",false,"NCT04934007","Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder","A Randomized Control Trial of Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder","ORBITOC3","Inclusion Criteria:\n\n* Age: Participants will be both males and females, 18-65 years of age included.\n* diagnosis of OCD\n* all the patients must have failed to respond to at least two different pharmacological treatment used for at least 6 weeks\n* Affiliation to a social security system (recipient or assignee),\n* Signed written inform consent form\n\nExclusion Criteria:\n\n* The exclusion criteria are a diagnosis of another psychiatric disorder (except for anxious disorders), a diagnosis of a significant active medical illness, pregnancy or other neurological illness\n* In accordance with the safety criteria for rTMS, patients with a history of seizure or bearing pacemakers, mobile metal implants, implanted medical pumps, or metal clips placed inside the skull will also be excluded\n* The patients won't be allowed to change their medication during the trial. The treatment must be stable at least 3 week before day 0.\n* Female subject who is pregnant, or of child-bearing age, sexually active and not using reliable contraception or who is nursing,\n* Patient under curators\n* Patient hospitalized under duress\n* Patient unable to give his or hers informed consent","ALL","18 Years","65 Years",{"count":114,"type":115},136,"ESTIMATED","INTERVENTIONAL",[118],"NA","According to the literature the lateral part of the Orbito Frontal Cortex (lOFC) is a relevant bilateral target for repetitive Trans-cranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD). Both hemispheres are concerned in terms of target.",[121],"Obsessive-Compulsive Disorder",[123,124],"rTMS","D-B80 A\u002FP","2026-01-12",{"date":127,"type":128},"2026-01-13","ACTUAL",{"date":130,"type":128},"2021-09-06",{"date":132,"type":115},"2027-09",{"name":5,"class":6},2]